What does SVOD stand for?

The company also has helped to fund Gentium SpA's Phase III defibrotide in hematopoietic stem cell transplant patients with severe veno-occlusive disease.

The cummulative incidences, of the secondary outcome measures, interstitial pneumonia, graft-vs-host disease, and transplantation-related mortality were similar between the treatment groups, as was the overall survival, and there was no apparent dose-effect relationships with the possible exception of severe veno-occlusive disease, which occurred more frequently as the immunoglobulin dose increased.

NASDAQ: GENT) announced today interim results from an independent Data Safety Monitoring Board (DSMB) review of the Company's Phase 3 treatment trial of Defibrotide for Severe Veno-Occlusive Disease (VOD).

The suit had attempted to block a financing transaction and was filed in the wake of concerns about the company's Phase III trial of defibrotide in hematopoietic stem cell transplant patients with severe veno-occlusive disease.

Food and Drug Administration to prevent and to treat severe veno-occlusive disease (VOD) and Fast Track designation for the treatment of severe VOD in recipients of stem cell transplants.

Byline: Tiffany Turner, Staff Writer Gentium SpA's stock dropped 27 percent Friday on news that an independent data safety monitoring board (DSMB) recommended that the company confirm the criteria used to select historical control patients for a Phase III trial of its lead product, defibrotide, in hematopoietic stem cell transplant patients with severe veno-occlusive disease (VOD).

Food and Drug Administration to treat Severe Veno-occlusive disease (VOD) and Orphan Medicinal Product Designation by the European Commission both to treat and to prevent VOD.

Food and Drug Administration to prevent and to treat severe veno-occlusive disease (VOD) and Fast Track designation for the treatment of severe VOD in recipients of stem cell transplants.